Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Change in Account Payables (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Change in Account Payables data on record, last reported at $1.5 million in Q4 2023.

  • For Q4 2023, Change in Account Payables rose 34.67% year-over-year to $1.5 million; the TTM value through Dec 2023 reached -$167000.0, up 67.19%, while the annual FY2025 figure was -$839000.0, 3.33% down from the prior year.
  • Change in Account Payables reached $1.5 million in Q4 2023 per CGEM's latest filing, up from -$1.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.5 million in Q4 2020 and bottomed at -$4.1 million in Q1 2021.
  • Average Change in Account Payables over 4 years is $4375.0, with a median of $315500.0 recorded in 2020.
  • Peak YoY movement for Change in Account Payables: plummeted 2525.88% in 2021, then skyrocketed 176.07% in 2022.
  • A 4-year view of Change in Account Payables shows it stood at $4.5 million in 2020, then tumbled by 74.65% to $1.1 million in 2021, then changed by 0.0% to $1.1 million in 2022, then soared by 34.67% to $1.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $1.5 million in Q4 2023, -$1.5 million in Q3 2023, and $461000.0 in Q2 2023.